Obesity pipeline
Studies
Trials grouped by drug. Open a study for its arms, the weeks a source actually reports, responder percents, and side effects.
624 studies across 92 of 94 drugs. 624 studies are in the file.
ABBV-2954 studies
- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Phase 2Recruitingn 360
- A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityNCT07291232Phase 1Active, not recruitingn 80
- A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.NCT07514260Phase 1Active, not recruitingn 24
- A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral ContraceptivesNCT07414784Phase 1Completedn 20
ACCG-26711 study
- First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671NCT07815678Phase 1/2Recruitingn 164
Albiglutide6 studies
- Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.NCT00537719Phase 1Completedn 34
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus SubjectsNCT02750930Phase 4Terminatedn 8
- Safety and Efficacy Study of Albiglutide in Type 2 DiabetesNCT00849017Phase 3Completedn 309
- A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy SubjectsNCT02496221Phase 4Completedn 20
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.NCT01098539Phase 3Completedn 507
- CER-4-T2DNCT05220917Phase n/rActive, not recruitingn 781430
Aleniglipron8 studies
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)NCT07654361Phase 3Recruitingn 3600
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374Phase 3Recruitingn 1100
- ACCESSNCT06693843Phase 2Completedn 230
- Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusNCT05762471Phase 1/2Completedn 142
- ACCESS IINCT06703021Phase 2Completedn 85
- Aleniglipron Phase 2 Body Composition StudyNCT07169942Phase 2Completedn 71
- GSBR-1290NCT07400588Phase 2Completedn 58
- A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsNCT06139055Phase 1Status n/rn 70
Apitegromab1 study
- EMBRAZENCT06445075Phase 2Completedn 102
ARO-ALK71 study
- NCT06937203NCT06937203Phase 1/2Recruitingn 150
ASC305 studies
- AURORA-1NCT07743463Phase 3Recruitingn 3003
- AURORA-2NCT07743450Phase 3Recruitingn 1560
- A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT07002905Phase 2Completedn 125
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With ObesityNCT06679959Phase 1/2Completedn 115
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With ObesityNCT06680440Phase 1Completedn 72
AZD62346 studies
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightNCT07017179Phase 2Active, not recruitingn 16
- SELENE 1NCT07784725Phase 3Recruitingn 2500
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseNCT06132841Phase 1Completedn 104
- SELENE-AsiaNCT07922330Phase 3Not yet recruitingn 330
- A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234NCT07911514Phase 1Not yet recruitingn 60
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel NCT07013643Phase 1Active, not recruitingn 100
Beinaglutide1 study
- The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.NCT05005741Phase 4Status n/rn 120
Beloranib6 studies
- Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female VolunteersNCT01028261Phase 1Completedn 31
- An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese SubjectsNCT01666691Phase 2Completedn 160
- An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic InjuryNCT02063295Phase 2Completedn 14
- bestPWSNCT02179151Phase 3Terminatedn 108
- An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi SyndromeNCT01818921Phase 2Completedn 17
- Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female VolunteersNCT01372761Phase 1Completedn 25
Berobenatide12 studies
- VESPER-4NCT07311850Phase 3Active, not recruitingn 3578
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)NCT07915609Phase 3Recruitingn 756
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500Phase 3Recruitingn 660
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)NCT07919678Phase 3Recruitingn 656
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or ObesityNCT07874633Phase 3Recruitingn 432
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or ObesityNCT07792954Phase 3Recruitingn 300
- VESPER-OSA 2NCT07881757Phase 3Recruitingn 258
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PNCT07823608Phase 3Recruitingn 258
- A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)NCT07794774Phase 3Recruitingn 197
- A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)NCT07794761Phase 3Recruitingn 180
- VESPER-3NCT06973720Phase 2Completedn 268
- VESPER-1NCT06712836Phase 2Completedn 239
BGM05048 studies
- A Study of BGM0504 Injection in Participants With Obesity or OverweightNCT06704581Phase 3Completedn 652
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesNCT07658560Phase 2Recruitingn 200
- A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsNCT06973681Phase 2Completedn 120
- A Study of BGM0504 in Participants With ObesityNCT06911203Phase 2Completedn 96
- A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.NCT07836140Phase 2Completedn 60
- Bioequivalence Study of BGM0504 InjectionNCT07382908Phase 1Completedn 144
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsNCT07166081Phase 1Completedn 80
- A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsNCT07239973Phase 1Completedn 75
Bimagrumab3 studies
- Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseNCT05616013Phase 2Completedn 507
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityNCT05933499Phase 2Recruitingn 63
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesNCT06901349Phase 2Withdrawnn 0
Bofanglutide8 studies
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsNCT06728124Phase 3Active, not recruitingn 630
- GZR18-BWM-303NCT07292441Phase 3Recruitingn 500
- Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsNCT07150975Phase 3Recruitingn 420
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyNCT07493057Phase 3Not yet recruitingn 140
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyNCT07501832Phase 3Not yet recruitingn 140
- A Study of GZR18 Injection in Obese/Overweight PatientsNCT06256562Phase 2Completedn 340
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsNCT06737042Phase 2Completedn 326
- A Study of GZR18 Injection in Chinese Obese/Overweight PatientsNCT06256536Phase 1/2Completedn 60
Brenipatide1 study
- A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityNCT07476118Phase 1Active, not recruitingn 150
Cagrilintide8 studies
- RENEW 2NCT07220759Phase 3Active, not recruitingn 330
- RENEW 1NCT07220642Phase 3Active, not recruitingn 300
- A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011Phase 1Completedn 178
- A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953Phase 1Recruitingn 120
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587Phase 1Recruitingn 114
- A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162Phase 1Completedn 107
- A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560Phase 1Recruitingn 100
- A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052Phase 1Completedn 50
Cagrilintide/semaglutide21 studies
- REDEFINE 1NCT05567796Phase 3Active, not recruitingn 3400
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Phase 3Recruitingn 2500
- REDEFINENCT07919405Phase 3Not yet recruitingn 1408
- REDEFINE 2NCT05394519Phase 3Completedn 1200
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437Phase 3Completedn 809
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Phase 3Active, not recruitingn 609
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Phase 3Recruitingn 460
- A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449Phase 3Active, not recruitingn 400
- A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925Phase 3Completedn 331
- A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187Phase 3Completedn 300
- REDEFINE 6NCT05996848Phase 3Completedn 300
- RENEW 4NCT07745504Phase 3Recruitingn 285
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766Phase 3Withdrawnn 0
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to SemagluNCT06131372Phase 2Completedn 626
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018Phase 1Recruitingn 234
- A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092Phase 1Completedn 164
- RAMBONCT07010432Phase 1Recruitingn 144
- RASMUSNCT07527195Phase 1Recruitingn 100
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086Phase 1Active, not recruitingn 80
- A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877Phase 1Completedn 62
- A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078Phase 1Completedn 40
Cetilistat1 study
- Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese SubjectsNCT00148382Phase 1Completedn 80
Cotadutide2 studies
- COTA China PKNCT05437848Phase 1Completedn 16
- Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusNCT04208620Phase 1Completedn 16
CRB-9131 study
- CANYON-1NCT07310901Phase 1Completedn 254
CT-3888 studies
- Enith-MACENCT07918846Phase 3Not yet recruitingn 8200
- Enith1NCT07351045Phase 3Recruitingn 2000
- Enith2NCT07351058Phase 3Recruitingn 1600
- A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416Phase 3Recruitingn 300
- ZYNERGYNCT07589686Phase 2Not yet recruitingn 486
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935Phase 2Completedn 469
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362Phase 2Completedn 447
- A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes MellitusNCT04838405Phase 1Completedn 129
CT-8684 studies
- A Study of CT-868 in Type 1 Diabetes MellitusNCT06062069Phase 2Completedn 111
- A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusNCT05110846Phase 2Completedn 103
- A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesNCT05794581Phase 1Completedn 32
- A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood GlucoseNCT04973111Phase 1Completedn 32
CT-9961 study
- Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes MellitusNCT05814107Phase 1Completedn 94
DA-17261 study
- First in Human Study in Subjects With Obesity, But Otherwise HealthyNCT06252220Phase 1Recruitingn 139
Danuglipron2 studies
- A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and RosuvastatiNCT06567327Phase 1Completedn 82
- A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or ObesityNCT06568731Phase 1Completedn 23
Dapiglutide2 studies
- DREAMNCT05788601Phase 2Active, not recruitingn 54
- A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of DapiglutideNCT06758583Phase 1Completedn 30
Dulaglutide11 studies
- Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111Phase 3Completedn 159
- Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesNCT07834398Phase 3Completedn 150
- Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide scNCT04189848Phase 4Completedn 104
- Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsNCT03743025Phase 4Terminatedn 28
- GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseNCT04387201Phase 4Completedn 23
- TIRZSEMA-CVOTNCT07096063Phase n/rCompletedn 887132
- Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495Phase n/rCompletedn 120000
- INTERCEPTNCT07417618Phase n/rCompletedn 60000
- Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using MetforminNCT04829903Not applicableCompletedn 116
- Semaglutide vs Dulaglutide on Epicardial Adipose TissueNCT04200625Phase n/rCompletedn 80
- The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With ObesityNCT06331286Not applicableStatus n/rn 60
Ecnoglutide5 studies
- A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityNCT05813795Phase 3Completedn 664
- A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)NCT07734311Phase 3Recruitingn 360
- A Study of Ecnoglutide Injection in Overweight or Obese Chinese AdolescentsNCT07836270Phase 3Not yet recruitingn 192
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07243171Phase 1/2Recruitingn 126
- XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy AdultsNCT05184322Phase 1Completedn 87
Efinopegdutide1 study
- A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)NCT06701305Phase 1Completedn 48
Efpeglenatide5 studies
- AMPLITUDE-SNCT03770728Phase 3Terminatedn 312
- AMPLITUDE-DNCT03684642Phase 3Terminatedn 908
- AMPLITUDE-MNCT03353350Phase 3Completedn 406
- AMPLITUDE-LNCT03713684Phase 3Terminatedn 370
- AMPLITUDE-ONCT03496298Phase 3Terminatedn 4076
Efsubaglutide Alfa5 studies
- The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)NCT06921486Phase 2/3Active, not recruitingn 1003
- The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)NCT07114419Phase 2Recruitingn 200
- LIGHTNCT06732960Phase 2Completedn 50
- Evaluating Anti-Obesity Medications 6 Months After Metabolic SurgeryNCT07163650Phase 4Recruitingn 60
- Phase Ib Study of Efsubaglutide Alfa Injection in Obese AdolescentsNCT07693426Phase 1Recruitingn 36
Elecoglipron4 studies
- EmboldNCT07667803Phase 3Recruitingn 4500
- ElecoglipronNCT07775404Phase 3Recruitingn 351
- A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsNCT07723833Phase 1Recruitingn 152
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsNCT07534592Phase 1Active, not recruitingn 48
Eloralintide14 studies
- NCT06230523NCT06230523Phase 2Completedn 263
- ENLIGHTEN-1NCT07321886Phase 3Recruitingn 1980
- ENLIGHTEN-10NCT07900633Phase 3Not yet recruitingn 3000
- ENLIGHTEN-2NCT07282600Phase 3Recruitingn 1035
- ENLIGHTEN-6NCT07392190Phase 3Recruitingn 900
- ENLIGHTEN-4NCT07353931Phase 3Recruitingn 900
- ENLIGHTEN-3NCT07369011Phase 3Recruitingn 800
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608Phase 2Recruitingn 400
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Phase 2Active, not recruitingn 200
- A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879Phase 1Recruitingn 115
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07765511Phase 1Not yet recruitingn 60
- A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614Phase 1Recruitingn 56
- A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightNCT07808060Phase 1Recruitingn 34
- A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightNCT06916091Phase 1Completedn 30
Eloralintide And Tirzepatide3 studies
- AMPLIFY-1NCT07881432Phase 3Not yet recruitingn 2115
- AMPLIFY-2NCT07881458Phase 3Recruitingn 1000
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityNCT06916065Phase 1Completedn 188
Enobosarm2 studies
Exenatide15 studies
- Effect on Weight Loss of Exenatide Versus PlaceboNCT00375492Phase 3Completedn 196
- Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsNCT03671733Phase 3Status n/rn 150
- The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsNCT00856609Phase 3Completedn 150
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)NCT02635386Phase 3Completedn 119
- BASIC2NCT04520490Phase 3Active, not recruitingn 63
- TAONCT01794429Phase 3Completedn 45
- CRANIOEXENCT02860923Phase 3Completedn 42
- ECHONCT02664441Phase 3Completedn 42
- AGREENCT00872378Phase 2/3Status n/rn 28
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsNCT03419624Phase 3Terminatedn 13
- A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsNCT00500370Phase 2Completedn 163
- Exenatide Once Weekly for Smoking CessationNCT02975297Phase 1/2Completedn 84
- Exenatide and Metformin Therapy in Overweight Women With PCOSNCT00344851Phase 2Completedn 60
- DapalostNCT02313220Phase 2Completedn 50
- Combat-JUDONCT02794402Phase 2Completedn 44
Garetosmab2 studies
- COURAGENCT06299098Phase 2Active, not recruitingn 1005
- Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal WomenNCT06970405Phase 1Withdrawnn 0
GUB0142951 study
- A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295NCT06144684Phase 1Completedn 76
HDM10025 studies
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese AdultsNCT06885021Phase 3Not yet recruitingn 780
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsNCT06500299Phase 2Status n/rn 180
- A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389Phase 1Recruitingn 111
- HDM1002 Tablets in Chinese Overweight and Obese Adult SubjectsNCT06520540Phase 1Status n/rn 72
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.NCT06601517Phase 1Status n/rn 30
HDM10058 studies
- Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesNCT07279194Phase 3Recruitingn 825
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep ApNCT07794397Phase 3Not yet recruitingn 200
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep ApNCT07787260Phase 3Not yet recruitingn 200
- Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes MellitusNCT06886126Phase 2Recruitingn 240
- A Pharmacokinetic Study of HDM1005 Injection at Different Injection SitesNCT07828197Phase 1Active, not recruitingn 135
- Phase Ib Clinical Study of HDM1005 InjectionNCT06637020Phase 1Completedn 80
- Phase Ia Clinical Study of HDM1005 InjectionNCT06640647Phase 1Completedn 65
- Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinNCT07502001Phase 1Not yet recruitingn 42
HDM17021 study
- Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsNCT07036172Phase 3Recruitingn 460
HM152112 studies
- A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDNCT03744182Phase 1Completedn 66
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)NCT03374241Phase 1Completedn 41
HS-200947 studies
- RISE-1NCT07896265Phase 3Not yet recruitingn 3000
- A Study of HS-20094 in Chinese Adults With Overweight or ObesityNCT06839664Phase 3Completedn 604
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Phase 2Recruitingn 360
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityNCT07830329Phase 2Not yet recruitingn 300
- A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT06118021Phase 2Completedn 200
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Phase 2Active, not recruitingn 120
- A Study of HS-20094 in Overweight or Obese ParticipantsNCT07057674Phase 1Recruitingn 144
LB546403 studies
- A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityNCT06046443Phase 2Completedn 28
- A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese SubjectsNCT06040372Phase 1Completedn 112
- A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic ObesityNCT06041841Phase 2Status n/rn 4
Liraglutide30 studies
- Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesNCT01272219Phase 3Completedn 3731
- Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesNCT01272232Phase 3Completedn 846
- Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceNCT00781937Phase 3Completedn 422
- The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight PatientsNCT04605861Phase 3Completedn 414
- SCALE™ InsulinNCT02963922Phase 3Completedn 396
- Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaNCT01557166Phase 3Completedn 359
- STEP 8NCT04074161Phase 3Completedn 338
- Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbiditiesNCT04525300Phase 3Status n/rn 300
- Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbiditiesNCT04487743Phase 3Status n/rn 300
- SCALE™ IBTNCT02963935Phase 3Completedn 282
- Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityNCT02918279Phase 3Completedn 251
- Individualized Obesity PharmacotherapyNCT03374956Phase 3Completedn 193
- Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityNCT05952882Phase 3Status n/rn 188
- Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908Phase 3Completedn 183
- Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)NCT01234649Phase 3Completedn 153
- LYDIANCT02043054Phase 3Completedn 90
- SAXAPCOSNCT03480022Phase 3Completedn 88
- Liraglutide In Overweight Patients With Type 1 DiabetesNCT01753362Phase 3Completedn 84
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082Phase 3Active, not recruitingn 78
- Effects of Benaglutide on Weight and Gut Microbiota in Obese PatientsNCT03986008Phase 3Status n/rn 60
- Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeNCT02527200Phase 3Completedn 56
- CGH-LiNASHNCT02654665Phase 3Status n/rn 36
- i-LABNCT02718950Phase 3Status n/rn 20
- Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese PatientsNCT04325581Phase 3Completedn 16
- Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon LiraglutidNCT02417103Phase 3Terminatedn 2
- Liraglutide Plus Megestrol Acetate in Endometrial Atypical HyperplasiaNCT04683237Phase 2/3Withdrawnn 0
- Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusNCT02453711Phase 2Completedn 957
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesNCT03235050Phase 2Completedn 834
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047Phase 2Completedn 706
- The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesNCT00422058Phase 2Completedn 564
Lixisenatide3 studies
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsNCT00976937Phase 3Completedn 319
- Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic PatientsNCT02274740Phase 2Terminatedn 2
- Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the BrainNCT02745470Not applicableCompletedn 30
Lorcaserin6 studies
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With ObesityNCT03799198Phase 4Completedn 200
- Predictors of Lorcaserin-Induced Weight LossNCT03353220Phase 4Terminatedn 32
- Lifestyle Modification and Lorcaserin for Weight Loss MaintenanceNCT02388568Not applicableCompletedn 137
- Lorcaserin: Real World Experience in an Insurance-Based Weight Management ClinicNCT03552107Phase n/rCompletedn 157
- CAMELLIA-TIMINCT02019264Phase 4Completedn 14673
- Lorcaserin for Preventing Weight Gain Among SmokersNCT02393547Phase 1/2Completedn 20
Lotiglipron6 studies
- A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 DruNCT05671653Phase 1Terminatedn 32
- A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult ParticipantsNCT05788328Phase 1Terminatedn 16
- A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese AdultsNCT05745701Phase 1Completedn 16
- Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityNCT05579977Phase 2Terminatedn 902
- Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusNCT05158244Phase 1Completedn 34
- A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or ObeseNCT05677867Phase 1Completedn 20
Loxenatide1 study
- Loxenatide Plus LNG-IUS in Endometrial Atypical HyperplasiaNCT05172999Phase 2/3Completedn 30
LY40869402 studies
- A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 DiabetesNCT07890376Phase 2Not yet recruitingn 460
- A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesNCT06945419Phase 1Completedn 219
Maridebart Cafraglutide17 studies
- NCT05669599NCT05669599Phase 2Completedn 592
- MARITIME-1NCT06858839Phase 3Active, not recruitingn 3853
- MARITIME-CVNCT07037433Phase 3Active, not recruitingn 12800
- MARITIME-HFNCT07037459Phase 3Recruitingn 5056
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235Phase 3Recruitingn 3200
- MARITIME-2NCT06858878Phase 3Active, not recruitingn 1105
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144Phase 3Recruitingn 950
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWNCT07575399Phase 3Recruitingn 300
- MARITIME-3-JNCT06987695Phase 3Active, not recruitingn 279
- MARITIME-OSA-1NCT07225686Phase 3Active, not recruitingn 250
- MARITIME-OSA-2NCT07226765Phase 3Active, not recruitingn 250
- MARITIME-PENNCT07871409Phase 3Not yet recruitingn 230
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173Phase 2Active, not recruitingn 409
- A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252Phase 2Active, not recruitingn 180
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesNCT07921316Phase 1Not yet recruitingn 356
- A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761Phase 1Completedn 349
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778Phase 1Completedn 348
Mazdutide20 studies
- A Study of IBI362 in Participants With Obesity or OverweightNCT05607680Phase 3Completedn 610
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)NCT06884293Phase 3Active, not recruitingn 479
- A Study of IBI362 9 mg in Chinese Adults With ObesityNCT06164873Phase 3Status n/rn 462
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityNCT06184568Phase 3Completedn 349
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800Phase 3Recruitingn 336
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028Phase 3Recruitingn 260
- A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209Phase 3Recruitingn 180
- A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT04904913Phase 2Completedn 328
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807Phase 2Completedn 179
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908Phase 2Active, not recruitingn 141
- MELIANCT07781150Phase 2Not yet recruitingn 128
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityNCT07000955Phase 1/2Active, not recruitingn 98
- Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsNCT04440345Phase 1/2Completedn 60
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676Phase 4Recruitingn 116
- PRIMENCT07718126Phase 4Recruitingn 60
- Mazdutide for Weight Management and Gout in Adults With ObesityNCT07824895Phase 4Not yet recruitingn 30
- A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680Phase 1Completedn 48
- This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityNCT06536023Phase 1Completedn 36
- Clinical Study of IBI362 in Healthy Chinese Male SubjectsNCT04773977Phase 1Completedn 24
- MOTIVE-AFNCT07897305Not applicableNot yet recruitingn 700
MDR-0014 studies
- A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)NCT07274137Phase 3Not yet recruitingn 738
- A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or OverweightNCT06606483Phase 2Status n/rn 300
- A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight ParticipantsNCT06778850Phase 1/2Completedn 128
- Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or OverweightNCT07110766Phase 1Not yet recruitingn 24
MET-233I2 studies
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320Phase 1/2Completedn 201
- A Study of MET233 in Individuals With Obesity or OverweightNCT07022977Phase 1Completedn 144
Monlunabant3 studies
- A Study to Explore the PK and PD of INV-202 in Metabolic SyndromeNCT05282446Phase 1Completedn 37
- A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian MenNCT06542536Phase 1Completedn 73
- Study of INV-202 in Patients With Obesity and Metabolic SyndromeNCT05891834Phase 2Completedn 243
Naltrexone And Bupropion12 studies
- A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsNCT00532779Phase 3Completedn 1742
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese SubjectsNCT00567255Phase 3Completedn 1496
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramNCT00456521Phase 3Completedn 793
- A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 DiabetesNCT00474630Phase 3Completedn 505
- Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute TreatmentNCT03045341Phase 2/3Completedn 136
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)NCT04599478Phase 2/3Completedn 92
- Pharmacological and Behavioral Treatment After Bariatric SurgeryNCT05157698Phase 3Completedn 84
- Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance TherapyNCT03047005Phase 2/3Completedn 68
- Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)NCT04605081Phase 2/3Completedn 24
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-RespondersNCT03946111Phase 2/3Completedn 3
- Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated ObesityNCT00364871Phase 2Completedn 410
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery PatientsNCT07398404Phase 1/2Not yet recruitingn 64
Nimacimab1 study
- CBeyondNCT06577090Phase 2Active, not recruitingn 136
NNC0165-18752 studies
- A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or ObeseNCT03707990Phase 1Completedn 88
- A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With ObesityNCT04969939Phase 2Completedn 120
NNC0519-01306 studies
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698Phase 2Recruitingn 465
- A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.NCT05363774Phase 1Completedn 161
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityNCT06718998Phase 1Completedn 134
- A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 DiabetesNCT06567041Phase 1Completedn 82
- A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the MedicineNCT06642571Phase 1Completedn 46
- A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body WeightNCT07004322Phase 1Completedn 20
Noiiglutide3 studies
- The Experiment of Noiiglutide Injection in Type 2 Diabetes PatientsNCT06649773Phase 3Completedn 137
- A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.NCT03848793Phase 2Completedn 128
- The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without DiabetesNCT04799327Phase 2Status n/rn 254
Oral Semaglutide5 studies
Oral VK27354 studies
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)NCT07868939Phase 3Not yet recruitingn 560
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)NCT07868835Phase 3Not yet recruitingn 560
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055Phase 2Completedn 280
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesNCT07838740Phase 1Recruitingn 270
Orforglipron23 studies
- ATTAIN-1NCT05869903Phase 3Active, not recruitingn 3127
- ACHIEVE-4NCT05803421Phase 3Completedn 2749
- ATTAIN-NOWNCT07794579Phase 3Recruitingn 2001
- ATTAIN-2NCT05872620Phase 3Completedn 1613
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792Phase 3Active, not recruitingn 1400
- RESTRAIN-SUINCT07202884Phase 3Recruitingn 1000
- A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422Phase 3Active, not recruitingn 974
- ATTAIN-OA PAINNCT07153471Phase 3Active, not recruitingn 800
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459Phase 3Active, not recruitingn 800
- ATTAIN-OSANCT06649045Phase 3Completedn 712
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472Phase 3Active, not recruitingn 600
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530Phase 3Active, not recruitingn 487
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435Phase 3Active, not recruitingn 487
- A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916Phase 3Completedn 376
- ATTAIN-JNCT05931380Phase 3Completedn 238
- ATTAIN-CNNCT07790861Phase 3Not yet recruitingn 192
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Phase 3Recruitingn 150
- ADVANCENCT06672549Phase 3Recruitingn 125
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332Phase 4Not yet recruitingn 60
- A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980Phase 1Completedn 533
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051Phase 1Completedn 120
- IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019Phase 1Recruitingn 104
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622Phase 1Completedn 50
Orlistat12 studies
- Evaluation of Orlistat as Adjuvant Treatment of Obesity in AdultsNCT01755676Phase 3Completedn 638
- FIT-PLESENCT02432209Phase 3Completedn 379
- A Study of Xenical (Orlistat) in Overweight and Obese AdolescentsNCT00940628Phase 3Completedn 60
- Effects of Weight Loss in Obese Difficult-to-treat AsthmaticsNCT01047657Phase 3Completedn 33
- Efficacy and Safety of ATL-962 in Obese DiabeticsNCT00156897Phase 2Completedn 600
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie DietNCT01126970Phase 2Completedn 486
- Study Exploring the Supportive Effect of Acarbose in Weight ManagementNCT05934110Phase 2Status n/rn 320
- Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related DiseasesNCT00001723Phase 2Completedn 200
- A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)NCT04521751Phase 1/2Completedn 156
- KGDobesityNCT02069197Phase 2Status n/rn 150
- REVIVENCT01351753Phase 2Terminatedn 128
- Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) PatientsNCT01003483Phase 2Completedn 80
Pemvidutide1 study
Petrelintide6 studies
- ZUPREME-4NCT07843485Phase 3Recruitingn 600
- ZUPREME-3NCT07843498Phase 3Recruitingn 3900
- ZUPREME-5NCT07843472Phase 3Recruitingn 2500
- ZUPREMENCT06662539Phase 2Completedn 493
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842Phase 2Completedn 221
- Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsNCT07338214Phase 1Completedn 48
PF-079760162 studies
- A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityNCT06717425Phase 2Completedn 263
- Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in NCT06910839Phase 1Terminatedn 21
Phentermine And Topiramate12 studies
- Study of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsNCT00554216Phase 3Completedn 1267
- A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsNCT00563368Phase 3Completedn 756
- SMARTNCT04007393Phase 2Completedn 150
- Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and LymphomaNCT07790913Phase 2Not yet recruitingn 100
- Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe ObesityNCT04298203Phase 2Completedn 100
- Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese PatientsNCT04721873Phase 2Recruitingn 40
- Qsymia as an Adjunct to Surgical Therapy in the SuperobeseNCT02301416Phase 2Completedn 25
- Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic ObesityNCT06299891Phase 2Active, not recruitingn 24
- Phentermine/Topiramate for Uric Acid StonesNCT04621929Phase 2Completedn 19
- Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year OldsNCT04095104Phase 2Completedn 13
- MAABS ProtocolNCT04572217Phase 2Withdrawnn 0
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249Phase 4Completedn 500
Pramlintide12 studies
- TOTTNCT06619015Phase 2/3Withdrawnn 0
- Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsNCT00673387Phase 2Completedn 636
- A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsNCT00112021Phase 2Completedn 400
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinNCT00819234Phase 2Completedn 274
- A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsNCT00402077Phase 2Completedn 258
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsNCT01235741Phase 2Terminatedn 213
- A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsNCT00189514Phase 2Completedn 210
- Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsNCT00444561Phase 2Completedn 184
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsNCT00392925Phase 2Completedn 177
- Evaluation of the Effect of Pramlintide on Satiety and Food IntakeNCT00042601Phase 2Completedn 51
- Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaNCT00690235Phase 4Completedn 33
- APPNCT07506369Not applicableRecruitingn 18
RAY12254 studies
- Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightNCT06893016Phase 3Recruitingn 640
- A Study of RAY1225 in Participants With ObesityNCT06254261Phase 2Recruitingn 270
- The Safety, Tolerability and Pharmacokinetic Study of RAY1225NCT05835752Phase 1Completedn 68
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and DigoxinNCT07362030Phase 1Active, not recruitingn 32
Retatrutide13 studies
- TRIUMPH-1NCT05929066Phase 3Completedn 2335
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Phase 3Active, not recruitingn 10000
- TRIUMPH-3NCT05882045Phase 3Completedn 1946
- TRIUMPH-2NCT05929079Phase 3Completedn 1152
- TRIUMPH-5NCT06662383Phase 3Active, not recruitingn 800
- TRIUMPH-6NCT06859268Phase 3Active, not recruitingn 643
- TRIUMPH-9NCT07357415Phase 3Active, not recruitingn 600
- TRIUMPH-7NCT07035093Phase 3Active, not recruitingn 586
- TRIUMPH-4NCT05931367Phase 3Completedn 445
- TRIUMPH-8NCT07232719Phase 3Active, not recruitingn 250
- GZBFNCT07467447Phase 2Recruitingn 300
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Phase 2Completedn 146
- Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401Phase n/rAvailablen n/r
Ribupatide10 studies
- KaiNETIC-1NCT07284875Phase 3Active, not recruitingn 2530
- KaiNETIC-2NCT07284901Phase 3Active, not recruitingn 1270
- A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884Phase 3Recruitingn 675
- To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObeseNCT06396429Phase 3Completedn 567
- A Trial of Ribupatide Injection in Participants With Obesity and Knee OsteoarthritisNCT07709910Phase 3Not yet recruitingn 382
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep ApnNCT06994650Phase 3Active, not recruitingn 144
- A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityNCT06974851Phase 3Recruitingn 140
- Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesNCT07458269Phase 2Active, not recruitingn 264
- A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesNCT05881837Phase 2Completedn 249
- HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection FractionNCT06391710Phase 2Active, not recruitingn 203
Rimonabant10 studies
- CRESCENDONCT00263042Phase 3Terminatedn 18695
- Obese Patients With or Without Comorbidities (RIO-North America)NCT00029861Phase 3Completedn 3045
- PRADONCT00405808Phase 3Terminatedn 2666
- Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)NCT00386061Phase 3Completedn 1507
- RIO-DiabetesNCT00029848Phase 3Completedn 1045
- RIO-LipidsNCT00029835Phase 3Completedn 1033
- Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)NCT00434096Phase 3Terminatedn 915
- STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)NCT00124332Phase 3Completedn 839
- ADAGIO-lipidsNCT00239967Phase 3Completedn 803
- AUDITORNCT00228176Phase 3Terminatedn 661
Safiglipron7 studies
- Phase III Study of HRS-7535 for Hypertension With Overweight or ObesityNCT07528027Phase 3Recruitingn 648
- A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityNCT06904105Phase 3Completedn 556
- Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .NCT06250946Phase 2Completedn 235
- Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and ObesityNCT06820099Phase 2Recruitingn 225
- Long-term Efficacy and Safety of HRS-7535 Tablets in Obese SubjectsNCT06671821Phase 2Completedn 81
- A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese SubjectsNCT06621316Phase 1/2Completedn 74
- A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight SubjectsNCT07269756Phase 1Completedn 40
Semaglutide37 studies
- STEP 1NCT03548935Phase 3Completedn 1961
- STEP UPNCT05646706Phase 3Completedn 1407
- SELECTNCT03574597Phase 3Completedn 17604
- MARITIME-T2D-3NCT07866066Phase 3Recruitingn 1300
- KaiNETIC-3NCT07284979Phase 3Active, not recruitingn 1270
- STEP 2NCT03552757Phase 3Completedn 1210
- AMAZE 8NCT07400107Phase 3Not yet recruitingn 1000
- STEP 4NCT03548987Phase 3Completedn 902
- SURMOUNT-5NCT05822830Phase 3Completedn 751
- AMAZE 7NCT07668414Phase 3Recruitingn 650
- STEP HFpEF DMNCT04916470Phase 3Completedn 617
- STEP 3NCT03611582Phase 3Completedn 611
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SNCT05514535Phase 3Completedn 573
- A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityNCT07285902Phase 3Active, not recruitingn 572
- STEP-HFpEFNCT04788511Phase 3Completedn 529
- A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightNCT05649137Phase 3Completedn 512
- Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes MellitusNCT06616961Phase 3Status n/rn 480
- Semaglutide in Treatment of ObesityNCT06604624Phase 3Completedn 462
- A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsNCT06738979Phase 3Completedn 408
- Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisNCT05064735Phase 3Completedn 407
- STEP 6NCT03811574Phase 3Completedn 401
- STEP7NCT04251156Phase 3Completedn 375
- A Study of BGM0504 in Early T2DM With ObesityNCT07743983Phase 3Recruitingn 372
- A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®NCT06633783Phase 3Status n/rn 370
- BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNCT07622810Phase 3Not yet recruitingn 352
- STEP 5NCT03693430Phase 3Completedn 304
- STEP12NCT06041217Phase 3Completedn 242
- STEP YoungNCT05726227Phase 3Active, not recruitingn 212
- STEP 10NCT05040971Phase 3Completedn 207
- A Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityNCT04102189Phase 3Completedn 201
- SEMINAL-AFNCT06499857Phase 3Recruitingn 200
- Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in YouthNCT06934655Phase 3Recruitingn 150
- Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With ObesityNCT04998136Phase 3Completedn 150
- SMARTNCT04889183Phase 3Completedn 125
- OBES1TYNCT06909006Phase 3Not yet recruitingn 122
- PLASTICNCT07021937Phase 3Not yet recruitingn 120
- LSSNCT05087342Phase 3Completedn 119
Setmelanotide15 studies
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634Phase 3Completedn 296
- Long Term Extension Trial of SetmelanotideNCT03651765Phase 2/3Completedn 205
- A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756Phase 3Active, not recruitingn 143
- Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522Phase 3Completedn 52
- A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546Phase 3Recruitingn 39
- Open-Label Extension Study of SetmelanotideNCT06596135Phase 3Completedn 28
- Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNCT05194124Phase 3Completedn 19
- Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityNCT03287960Phase 3Completedn 15
- Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192Phase 3Completedn 15
- Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741Phase 3Completedn 12
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543Phase 2Completedn 213
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231Phase 2Completedn 164
- Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsNCT02041195Phase 1/2Completedn 99
- Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137Phase 2Completedn 74
- Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673Phase 2Completedn 40
Sibutramine8 studies
- SCOUTNCT00234832Phase 3Completedn 10777
- A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.NCT00261911Phase 3Completedn 498
- Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese SubjectsNCT00645255Phase 3Terminatedn 466
- A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating DisorderNCT00402584Phase 3Completedn 304
- A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese SubjectsNCT00134199Phase 2/3Completedn 282
- HOSNCT00679653Phase 3Completedn 171
- Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian PopulationNCT00677391Phase 3Completedn 103
- Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese PatientsNCT00941382Phase 3Status n/rn 60
Supaglutide5 studies
- A Study of the Efficacy and Safety of Supaglutide in Healthy ParticipantsNCT03745885Phase 1Completedn 48
- A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)NCT04998032Phase 2/3Completedn 620
- A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)NCT04994288Phase 2/3Completedn 547
- A Study of Supaglutide in Chinese Type 2 Diabetes PatientsNCT04314622Phase 2Completedn 40
- The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes PatientsNCT06605287Phase n/rStatus n/rn 100
Survodutide21 studies
- SYNCHRONIZE-1NCT06066515Phase 3Completedn 726
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864Phase 3Completedn 5530
- SYNCHRONIZE™-2NCT06066528Phase 3Completedn 755
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063Phase 3Not yet recruitingn 600
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050Phase 3Not yet recruitingn 600
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900Phase 3Not yet recruitingn 350
- A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741Phase 3Completedn 307
- SYNCHRONIZE™JPNCT06176365Phase 3Completedn 274
- A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to RedNCT06309992Phase 3Completedn 218
- A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377Phase 2Completedn 387
- A Study to Test Different Doses of BI 456906 in Patients With ObesityNCT03591718Phase 1Completedn 131
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467Phase 1Completedn 110
- A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906NCT05751226Phase 1Completedn 88
- A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and WithNCT05296733Phase 1Completedn 82
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284Phase 1Active, not recruitingn 64
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-NCT07413913Phase 1Completedn 56
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813Phase 1Active, not recruitingn 44
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441Phase 1Completedn 34
- A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodNCT05896384Phase 1Completedn 32
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135Phase 1Completedn 30
- A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353Phase 1Active, not recruitingn 29
Taldefgrobep1 study
- Taldefgrobep Alfa in Adults With Overweight and ObesityNCT07281495Phase 2Active, not recruitingn 150
Taspoglutide1 study
TERN-6011 study
- FALCONNCT06854952Phase 2Completedn 167
Tesofensine4 studies
- Effect of Tesofensine on Weight Reduction in Patients With Obesity.NCT00394667Phase 2Completedn 200
- Evaluation of Long Term Safety of Tesofensine in Patients With ObesityNCT00481104Phase 2Completedn 140
- Effect of Tesofensine on Energy Balance in Humans.NCT00428415Phase 1/2Completedn 32
- 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)NCT03845075Phase 2Completedn 21
TG1035 studies
- A Study of TG103 Injection in Non-diabetic Overweight or ObesityNCT05997576Phase 3Completedn 675
- A Study of TG103 Injection in the Management of Non-diabetic Overweight or ObesityNCT06226090Phase 2Completedn 314
- A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 DiabetesNCT05063253Phase 2Status n/rn 208
- A Study of TG103 Injection in Overweight or ObesityNCT05299697Phase 2Status n/rn 195
- A Study of TG103 Injection in Overweight/Obese Subjects Without DiabetesNCT04855292Phase 1Completedn 48
Tirzepatide41 studies
- SURMOUNT-1NCT04184622Phase 3Completedn 2539
- SURMOUNT-MMONCT05556512Phase 3Active, not recruitingn 15374
- SURMOUNT-1NCT07481747Phase 3Recruitingn 2539
- SURMOUNT-2NCT04657003Phase 3Completedn 938
- SURPASS-T1D-1NCT06914895Phase 3Active, not recruitingn 905
- SURMOUNT-4NCT04660643Phase 3Completedn 783
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557Phase 3Completedn 731
- SURMOUNT-3NCT04657016Phase 3Completedn 579
- SURMOUNT-OSANCT05412004Phase 3Completedn 469
- SURPASS-T1D-2NCT06962280Phase 3Active, not recruitingn 465
- A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06047548Phase 3Completedn 441
- Efficacy and Safety of Tirzepatide for Weight ManagementNCT06918405Phase 3Active, not recruitingn 440
- COMMIT-UCNCT06937086Phase 3Recruitingn 350
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Phase 3Recruitingn 300
- COMMIT-CDNCT06937099Phase 3Recruitingn 290
- TOGETHER-PsONCT06588283Phase 3Completedn 281
- TOGETHER-PsANCT06588296Phase 3Completedn 279
- SURMOUNT-JNCT04844918Phase 3Completedn 267
- TIRZE-PAPNCT07846865Phase 2/3Not yet recruitingn 256
- SURMOUNT-CNNCT05024032Phase 3Completedn 210
- A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667Phase 3Active, not recruitingn 160
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMNCT07817875Phase 3Recruitingn 150
- TZPNCT07284511Phase 2/3Recruitingn 105
- TirBaSNCT07829198Phase 3Not yet recruitingn 70
- DUAL-HFrEFNCT07738276Phase 3Not yet recruitingn 60
- GRABS-0NCT06162715Phase 2/3Active, not recruitingn 30
- EXER-MEDNCT07298915Phase 3Not yet recruitingn 24
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956Phase 2Recruitingn 1481
- A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityNCT06037252Phase 2Active, not recruitingn 414
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityNCT06373146Phase 2Completedn 392
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesNCT07521631Phase 2Recruitingn 372
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571Phase 2Completedn 367
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightNCT06326060Phase 2Completedn 354
- GYMINDANCT06965413Phase 2Active, not recruitingn 285
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightNCT06643728Phase 2Active, not recruitingn 252
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or ObeseNCT06732245Phase 2Not yet recruitingn 224
- STRIDESNCT06515418Phase 2Terminatedn 204
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538Phase 1/2Active, not recruitingn 190
- Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm HealthNCT07179120Phase 2Not yet recruitingn 180
- A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Phase 1/2Recruitingn 156
- TREASURE-CKDNCT05536804Phase 2Completedn 134
UBT2518 studies
- UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)NCT07648225Phase 3Active, not recruitingn 600
- UNISHAPE-OSA-1NCT07767942Phase 3Not yet recruitingn 150
- UNISHAPE-OSA-2NCT07806851Phase 3Not yet recruitingn 150
- A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityNCT07395687Phase 2Recruitingn 333
- UBT251 Injection Phase II Study (Overweight or Obesity)NCT07177469Phase 2Completedn 205
- UBT251 Injection Phase II Clinical Study (CKD)NCT07134335Phase 2Recruitingn 180
- Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityNCT07785934Phase 1Recruitingn 48
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNCT07710768Phase 1Recruitingn 44
VCT2206 studies
- A Research Study of VCT220 in Adult Chinese Participants With ObesityNCT06939296Phase 3Completedn 840
- A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese PopulationNCT06569355Phase 2Completedn 250
- VICTOR-HTNNCT07360275Phase 2Active, not recruitingn 160
- A Food-Effect Study of CX11 in Healthy ParticipantsNCT07349381Phase 1Completedn 32
- This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or ItraconazoleNCT07056842Phase 1Completedn 32
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese SubjectsNCT07065058Phase 1Completedn 24
Velneperit3 studies
- OLENCT00788528Phase 2Completedn 766
- Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie DietNCT00748605Phase 2Completedn 842
- Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie DietNCT00747929Phase 2Completedn 724
Visepegenatide1 study
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese SubjectsNCT06350812Phase 1/2Completedn 32
VK27353 studies
- VENTURENCT06068946Phase 2Completedn 176
- VANQUISH 1NCT07104500Phase 3Active, not recruitingn 4500
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383Phase 3Active, not recruitingn 1100
VRB-1013 studies
- EVOLVE-2NCT07281937Phase 2Completedn 206
- A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299Phase 2Terminatedn 8
- A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or OverweightNCT07628127Phase 1Recruitingn 332
Zenagamtide6 studies
- AMAZE 9NCT07720271Phase 3Recruitingn 950
- AMBIENCENCT07861100Phase 3Not yet recruitingn 8500
- AMAZE 13NCT07668401Phase 3Not yet recruitingn 400
- A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With OverweNCT07815067Phase 1Recruitingn 320
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current TirzepNCT07868354Phase 1Recruitingn 60
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current SemaglNCT07855133Phase 1Recruitingn 60